Agenda of the HMPC meeting 23-25 September 2024
Submitted by Anonymous (not verified) on 23 September 2024 - 15:30
Agenda of the HMPC meeting 23-25 September 2024
Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Date of authorisation: 30/04/2021, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 23 September 2024 - 15:29
Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Date of authorisation: 30/04/2021, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 23 September 2024 - 15:18
Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Authorised
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024
Submitted by Anonymous (not verified) on 23 September 2024 - 14:45
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024
CHMP PROM minutes for the meeting on 17 June 2024
Submitted by Anonymous (not verified) on 23 September 2024 - 14:31
CHMP PROM minutes for the meeting on 17 June 2024
Human medicines European public assessment report (EPAR): Insulin aspart Sanofi, insulin aspart, Date of authorisation: 25/06/2020, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 23 September 2024 - 14:02
Human medicines European public assessment report (EPAR): Insulin aspart Sanofi, insulin aspart, Date of authorisation: 25/06/2020, Revision: 6, Status: Authorised
Agenda - Information session on the pilot for expert panels' advice for orphan medical devices
Submitted by Anonymous (not verified) on 23 September 2024 - 12:30
Agenda - Information session on the pilot for expert panels' advice for orphan medical devices
Scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products, regarding the list of substances essential for the treatment of equine species and for which the withdrawal period for equine species shall be six months
Submitted by Anonymous (not verified) on 23 September 2024 - 12:30
Scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products, regarding the list of substances essential for the treatment of equine species and for which the withdrawal period for equine species shall be six months
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) - 22 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 October 2024, 10:00 (CEST) to 22 October 2024, 10:30 (CEST)
Submitted by Anonymous (not verified) on 23 September 2024 - 11:48
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) - 22 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 October 2024, 10:00 (CEST) to 22 October 2024, 10:30 (CEST)
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 29 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 October 2024, 10:00 (CET) to 29 October 2024,
Submitted by Anonymous (not verified) on 23 September 2024 - 11:40
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 29 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 October 2024, 10:00 (CET) to 29 October 2024, 10:30 (CET)